Review



monoclonal primary antibodies against olig2  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    R&D Systems monoclonal primary antibodies against olig2
    Panel A: Radial plot showing the expression of oligodendroglial markers in the two groups of DIPG, in log2 ratios related each other. The red circle represent the median expression level of the whole population of DIPG. Group 1 expresses higher levels of oligodendroglial markers than group 2 DIPG. Panel B: Morphological oligodendroglial differenciation in group 1 tumors (HES staining, ×40). Panel C: Morphological astrocytic differenciation in group 2 tumors (HES staining ×40). Panel D: <t>Olig2</t> immunohistochemistry in a group 1 DIPG showing that probably not all cells in the biopsy are tumoral (×40). Panel E: Dual immunohistochemistry for Olig2 and GFAP showing that tumor cells in mitosis are GFAP negative but Olig2 positive (×100). Panel F: Overall survival of 55 DIPG according to the presence (red) or absence (blue) of oligodendroglial differenciation. Median OS was shorter in patients with oligodendroglial type of tumors (7.73 vs 12.37, p = 0.045, log rank test).
    Monoclonal Primary Antibodies Against Olig2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 461 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+primary+antibodies+against+olig2/Human%2FMouse%2FRat+Olig2+Antibody/pmc03289615-199-7-15
    Average 96 stars, based on 461 article reviews
    monoclonal primary antibodies against olig2 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas"

    Article Title: Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0030313

    Panel A: Radial plot showing the expression of oligodendroglial markers in the two groups of DIPG, in log2 ratios related each other. The red circle represent the median expression level of the whole population of DIPG. Group 1 expresses higher levels of oligodendroglial markers than group 2 DIPG. Panel B: Morphological oligodendroglial differenciation in group 1 tumors (HES staining, ×40). Panel C: Morphological astrocytic differenciation in group 2 tumors (HES staining ×40). Panel D: Olig2 immunohistochemistry in a group 1 DIPG showing that probably not all cells in the biopsy are tumoral (×40). Panel E: Dual immunohistochemistry for Olig2 and GFAP showing that tumor cells in mitosis are GFAP negative but Olig2 positive (×100). Panel F: Overall survival of 55 DIPG according to the presence (red) or absence (blue) of oligodendroglial differenciation. Median OS was shorter in patients with oligodendroglial type of tumors (7.73 vs 12.37, p = 0.045, log rank test).
    Figure Legend Snippet: Panel A: Radial plot showing the expression of oligodendroglial markers in the two groups of DIPG, in log2 ratios related each other. The red circle represent the median expression level of the whole population of DIPG. Group 1 expresses higher levels of oligodendroglial markers than group 2 DIPG. Panel B: Morphological oligodendroglial differenciation in group 1 tumors (HES staining, ×40). Panel C: Morphological astrocytic differenciation in group 2 tumors (HES staining ×40). Panel D: Olig2 immunohistochemistry in a group 1 DIPG showing that probably not all cells in the biopsy are tumoral (×40). Panel E: Dual immunohistochemistry for Olig2 and GFAP showing that tumor cells in mitosis are GFAP negative but Olig2 positive (×100). Panel F: Overall survival of 55 DIPG according to the presence (red) or absence (blue) of oligodendroglial differenciation. Median OS was shorter in patients with oligodendroglial type of tumors (7.73 vs 12.37, p = 0.045, log rank test).

    Techniques Used: Expressing, Staining, Immunohistochemistry

    Related Articles

    Incubation:

    Article Title: Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas
    Article Snippet: A semi-automatised system using a microwave antigen retrieval (MicroMED T/T Mega; Hacker Instruments & Industries, Inc., Winnsboro, SC) for 30 minutes at 98°C (manufacturer recommendations) and the RTU Vectastain Universal detection system (Vector laboratories, Burligame, CA, USA) for Olig2. .. Sections were then incubated with various commercial monoclonal primary antibodies against Olig2 (AF 2418, 1/150, R/D system, CA, USA), P53 (DO-1, 1/1, Ventana) and MIB-1 (1/100; Dako, Glostrup, Denmark). ..



    Similar Products

    primary monoclonal antibodies against olig2  (GeneTex)
    90
    GeneTex primary monoclonal antibodies against olig2
    Demographic characteristics and of cGBM patients.
    Primary Monoclonal Antibodies Against Olig2, supplied by GeneTex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+primary+antibodies+against+olig2/anti+olig2/pmc10126729-87-9-10
    Average 90 stars, based on 1 article reviews
    primary monoclonal antibodies against olig2 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    monoclonal primary antibodies against olig2  (R&D Systems)
    96
    R&D Systems monoclonal primary antibodies against olig2
    Panel A: Radial plot showing the expression of oligodendroglial markers in the two groups of DIPG, in log2 ratios related each other. The red circle represent the median expression level of the whole population of DIPG. Group 1 expresses higher levels of oligodendroglial markers than group 2 DIPG. Panel B: Morphological oligodendroglial differenciation in group 1 tumors (HES staining, ×40). Panel C: Morphological astrocytic differenciation in group 2 tumors (HES staining ×40). Panel D: <t>Olig2</t> immunohistochemistry in a group 1 DIPG showing that probably not all cells in the biopsy are tumoral (×40). Panel E: Dual immunohistochemistry for Olig2 and GFAP showing that tumor cells in mitosis are GFAP negative but Olig2 positive (×100). Panel F: Overall survival of 55 DIPG according to the presence (red) or absence (blue) of oligodendroglial differenciation. Median OS was shorter in patients with oligodendroglial type of tumors (7.73 vs 12.37, p = 0.045, log rank test).
    Monoclonal Primary Antibodies Against Olig2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+primary+antibodies+against+olig2/Human%2FMouse%2FRat+Olig2+Antibody/pmc03289615-199-7-15
    Average 96 stars, based on 1 article reviews
    monoclonal primary antibodies against olig2 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Demographic characteristics and of cGBM patients.

    Journal: Clinics

    Article Title: OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)

    doi: 10.1016/j.clinsp.2022.100120

    Figure Lengend Snippet: Demographic characteristics and of cGBM patients.

    Article Snippet: Primary monoclonal antibodies against the following antigens were used: Olig2 (Genetex, Texas, US).

    Techniques: Biomarker Discovery, Expressing, Adjuvant

    OLIG2 expression on immunohistochemistry. The intensity of OLIG2 is varied from 0 to 3 in Figure A to Figure D (magnification × 400-fold).

    Journal: Clinics

    Article Title: OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)

    doi: 10.1016/j.clinsp.2022.100120

    Figure Lengend Snippet: OLIG2 expression on immunohistochemistry. The intensity of OLIG2 is varied from 0 to 3 in Figure A to Figure D (magnification × 400-fold).

    Article Snippet: Primary monoclonal antibodies against the following antigens were used: Olig2 (Genetex, Texas, US).

    Techniques: Expressing, Immunohistochemistry

    Correlation of OLIG2 expression level to cGBM patients’ demographic characteristics.

    Journal: Clinics

    Article Title: OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)

    doi: 10.1016/j.clinsp.2022.100120

    Figure Lengend Snippet: Correlation of OLIG2 expression level to cGBM patients’ demographic characteristics.

    Article Snippet: Primary monoclonal antibodies against the following antigens were used: Olig2 (Genetex, Texas, US).

    Techniques: Expressing, Biomarker Discovery

    Kaplan-Meier analysis results of the OS of cGBM patients.

    Journal: Clinics

    Article Title: OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)

    doi: 10.1016/j.clinsp.2022.100120

    Figure Lengend Snippet: Kaplan-Meier analysis results of the OS of cGBM patients.

    Article Snippet: Primary monoclonal antibodies against the following antigens were used: Olig2 (Genetex, Texas, US).

    Techniques: Expressing, Adjuvant

    Kaplan-Meier analysis showed the high expression of OLIG2 had favorable OS for those cGBM patients.

    Journal: Clinics

    Article Title: OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)

    doi: 10.1016/j.clinsp.2022.100120

    Figure Lengend Snippet: Kaplan-Meier analysis showed the high expression of OLIG2 had favorable OS for those cGBM patients.

    Article Snippet: Primary monoclonal antibodies against the following antigens were used: Olig2 (Genetex, Texas, US).

    Techniques: Expressing

    Cox regression analysis for the risk factors on the OS of cGBM patients.

    Journal: Clinics

    Article Title: OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM)

    doi: 10.1016/j.clinsp.2022.100120

    Figure Lengend Snippet: Cox regression analysis for the risk factors on the OS of cGBM patients.

    Article Snippet: Primary monoclonal antibodies against the following antigens were used: Olig2 (Genetex, Texas, US).

    Techniques: Expressing, Adjuvant

    Panel A: Radial plot showing the expression of oligodendroglial markers in the two groups of DIPG, in log2 ratios related each other. The red circle represent the median expression level of the whole population of DIPG. Group 1 expresses higher levels of oligodendroglial markers than group 2 DIPG. Panel B: Morphological oligodendroglial differenciation in group 1 tumors (HES staining, ×40). Panel C: Morphological astrocytic differenciation in group 2 tumors (HES staining ×40). Panel D: Olig2 immunohistochemistry in a group 1 DIPG showing that probably not all cells in the biopsy are tumoral (×40). Panel E: Dual immunohistochemistry for Olig2 and GFAP showing that tumor cells in mitosis are GFAP negative but Olig2 positive (×100). Panel F: Overall survival of 55 DIPG according to the presence (red) or absence (blue) of oligodendroglial differenciation. Median OS was shorter in patients with oligodendroglial type of tumors (7.73 vs 12.37, p = 0.045, log rank test).

    Journal: PLoS ONE

    Article Title: Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas

    doi: 10.1371/journal.pone.0030313

    Figure Lengend Snippet: Panel A: Radial plot showing the expression of oligodendroglial markers in the two groups of DIPG, in log2 ratios related each other. The red circle represent the median expression level of the whole population of DIPG. Group 1 expresses higher levels of oligodendroglial markers than group 2 DIPG. Panel B: Morphological oligodendroglial differenciation in group 1 tumors (HES staining, ×40). Panel C: Morphological astrocytic differenciation in group 2 tumors (HES staining ×40). Panel D: Olig2 immunohistochemistry in a group 1 DIPG showing that probably not all cells in the biopsy are tumoral (×40). Panel E: Dual immunohistochemistry for Olig2 and GFAP showing that tumor cells in mitosis are GFAP negative but Olig2 positive (×100). Panel F: Overall survival of 55 DIPG according to the presence (red) or absence (blue) of oligodendroglial differenciation. Median OS was shorter in patients with oligodendroglial type of tumors (7.73 vs 12.37, p = 0.045, log rank test).

    Article Snippet: Sections were then incubated with various commercial monoclonal primary antibodies against Olig2 (AF 2418, 1/150, R/D system, CA, USA), P53 (DO-1, 1/1, Ventana) and MIB-1 (1/100; Dako, Glostrup, Denmark).

    Techniques: Expressing, Staining, Immunohistochemistry